Review of obesity pharmacotherapy advancements and challenges covers GLP-1/GIP drugs, emerging agents, access barriers, and the evolving treatment landscape.
Key findingReview of obesity pharmacotherapy advancements and challenges covers GLP-1/GIP drugs, emerging agent
What the researchers found
Review of obesity pharmacotherapy advancements and challenges covers GLP-1/GIP drugs, emerging agents, access barriers, and the evolving treatment landscape.
Why it matters
Relevant to peptide-based therapeutic applications.
The numbers in context
Review covers the global increase in obesity prevalence and the expanding pharmacotherapy options available to address it.
How the study worked
Methodology in publication.
Who was studied
Adults with obesity across reviewed clinical trials and real-world studies
What this study cannot tell us
Limitations in publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Contributes to peptide therapeutic evidence.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Advancements and challenges in the management of obesity using pharmacotherapy (Review).
Experimental and therapeutic medicine, 30(2), 162
Citation
Alotaibi, Saqer S; Eldrehmy, Essam H; Albogami, Sarah M; Alkhedaide, Adel; Dahab, Omima. (2025). Advancements and challenges in the management of obesity using pharmacotherapy (Review).. Experimental and therapeutic medicine, 30(2), 162. https://doi.org/10.3892/etm.2025.12912